Zevra Therapeutics Inc. (ZVRA) Stock Forecast & Price Target
Zevra Therapeutics Inc. · NASDAQ
$12.67+0.27 (+2.18%)
15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 7 firms covering Zevra Therapeutics Inc, 7 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $20.00 to $35.00, a moderate spread. The average target of $27.14 sits 114% above the current $12.67. The rating mix has stayed broadly stable, with Buy-side ratings easing from 8 to 7 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.19 next quarter toward $1.08 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 ratings
Strong Buy
Strong Buy00%
Buy7100%
Hold00%
Sell00%
Strong Sell00%
Based on 7 analysts giving stock ratings to Zevra Therapeutics Inc.
As of Sep, 7 of 7 firms rate ZVRA a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ZVRA EPS & revenue forecast
EPS · NEXT QUARTER
$0.19
Range $0.16 – $0.22 · 3 analysts · +2% YoY
Next period, 3 analysts expect Zevra Therapeutics Inc. to earn $0.19 a share (range $0.16 – $0.22), versus $0.19 a year earlier. Full-year consensus is $1.17, growing to $1.08 the year after.
REVENUE · NEXT QUARTER
$40.2M
Range $38.3M – $41.9M · 3 analysts · +18% YoY
Revenue is expected to reach $40.2M (range $38.3M – $41.9M), +17.8% year-over-year. Full-year consensus is $153.3M, rising to $177.7M next year.
Top analysts covering Zevra Therapeutics Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ZVRA.
#1
Jason Butler
JMP Securities · Rank #31
Buy
$25.00+97.3% to target
Overall win rate
53%
+ Follow
#2
Kristen Kluska
Cantor Fitzgerald · Rank #169
Buy
$25.00+97.3% to target
Overall win rate
38%
+ Follow
#3
Oren Livnat
HC Wainwright & Co. · Rank #170
Buy
$20.00+57.9% to target
Overall win rate
54%
+ Follow
#4
Louise Chen
Cantor Fitzgerald · Rank #183
Buy
No targeton ZVRA
Overall win rate
43%
+ Follow
#5
BF
Brandon Folkes
HC Wainwright & Co. · Rank #221
Buy
$26.00+105.2% to target
Overall win rate
42%
+ Follow
ZVRA stock forecast FAQ
What is ZVRA's average 12-month price target?+
The 7 analysts with a live target average $27.14 for Zevra Therapeutics Inc. over the next 12 months, ranging from a $35.00 high to a $20.00 low.
Is ZVRA stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 7 analyst ratings, 7 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for ZVRA?+
The Street-high target is $35.00 (Maxim Group), and the Street-low is $20.00 (Canaccord Genuity). The average of all 7 active targets is $27.14.
How many Wall Street analysts cover ZVRA?+
7 analysts have an active rating on Zevra Therapeutics Inc., and 7 firms carry a live 12-month price target.
Who is the most accurate analyst covering ZVRA?+
Among analysts who currently cover ZVRA, Jason Butler of JMP Securities has the strongest overall Quantellect track record (Rank #31). Their current call is Buy with a $25.00 target.
What is Zevra Therapeutics Inc.'s projected EPS for next quarter?+
The consensus estimate is $0.19 per share (range $0.16 – $0.22) across 3 analysts. Full-year EPS is projected at $1.17, rising to $1.08 the following year.
How much revenue is Zevra Therapeutics Inc. expected to report next quarter?+
Consensus revenue is $40.2M (range $38.3M – $41.9M). Full-year revenue is projected at $153.3M, growing to $177.7M next year.
Have analysts been upgrading or downgrading ZVRA lately?+
As of Sep, 7 of 7 firms rate ZVRA a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ZVRA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
